$LRMR
Larimar Therapeutics, Inc.

2018 Q2 Form 10-Q Financial Statement

#000119312518159281 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.350M $3.270M $3.590M
YoY Change 11.3% -8.91% -33.02%
% of Gross Profit
Research & Development $12.21M $12.43M $9.677M
YoY Change 15.97% 28.48% -22.57%
% of Gross Profit
Depreciation & Amortization $50.00K $50.00K $41.00K
YoY Change 0.0% 21.95% -18.0%
% of Gross Profit
Operating Expenses $15.56M $15.70M $13.27M
YoY Change 14.95% 18.37% -25.72%
Operating Profit -$15.56M -$15.70M -$13.27M
YoY Change 14.95% 18.37% -25.72%
Interest Expense $466.0K $458.0K $73.00K
YoY Change 779.25% 527.4% -54.38%
% of Operating Profit
Other Income/Expense, Net -$215.0K -$254.0K $254.0K
YoY Change -213.76% -200.0% 109.92%
Pretax Income -$15.78M -$15.96M -$13.01M
YoY Change 18.2% 22.67% -26.66%
Income Tax
% Of Pretax Income
Net Earnings -$15.78M -$15.96M -$13.01M
YoY Change 18.19% 22.63% -26.64%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$6.861M -$6.939M -$5.706M
COMMON SHARES
Basic Shares Outstanding 27.56M shares 27.56M shares 27.35M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.85M $89.07M $120.7M
YoY Change -28.44% -26.18% -27.4%
Cash & Equivalents $40.75M $45.73M $32.35M
Short-Term Investments $35.10M $43.34M $88.30M
Other Short-Term Assets $1.300M $1.400M $1.400M
YoY Change -18.75% 0.0% 7.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $78.03M $91.42M $118.7M
YoY Change -27.72% -22.97% -29.71%
LONG-TERM ASSETS
Property, Plant & Equipment $472.0K $479.0K $630.0K
YoY Change -19.73% -23.97% -33.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $357.0K $132.0K $59.00K
YoY Change 515.52% 123.73% -34.44%
Total Long-Term Assets $1.767M $1.192M $689.0K
YoY Change 100.8% 73.0% -42.0%
TOTAL ASSETS
Total Short-Term Assets $78.03M $91.42M $118.7M
Total Long-Term Assets $1.767M $1.192M $689.0K
Total Assets $79.80M $92.61M $119.4M
YoY Change -26.68% -22.41% -29.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.010M $3.796M $1.910M
YoY Change -32.31% 98.74% -39.29%
Accrued Expenses $4.448M $3.661M $3.850M
YoY Change 64.19% -4.91% -42.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $400.0K
YoY Change -100.0%
Long-Term Debt Due $1.800M $2.400M
YoY Change -14.29% -20.0%
Total Short-Term Liabilities $9.276M $7.457M $8.597M
YoY Change 0.62% -13.26% -33.26%
LONG-TERM LIABILITIES
Long-Term Debt $18.50M $20.20M $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $18.50M $20.20M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.276M $7.457M $8.597M
Total Long-Term Liabilities $18.50M $20.20M $0.00
Total Liabilities $27.78M $27.62M $8.597M
YoY Change 201.31% 221.24% -44.91%
SHAREHOLDERS EQUITY
Retained Earnings -$321.3M -$305.5M -$250.6M
YoY Change 21.75% 21.94% 26.93%
Common Stock $373.3M $370.6M $361.4M
YoY Change 2.69% 2.54% 2.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.02M $65.00M $110.8M
YoY Change
Total Liabilities & Shareholders Equity $79.80M $92.61M $119.4M
YoY Change -26.68% -22.41% -29.79%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$15.78M -$15.96M -$13.01M
YoY Change 18.19% 22.63% -26.64%
Depreciation, Depletion And Amortization $50.00K $50.00K $41.00K
YoY Change 0.0% 21.95% -18.0%
Cash From Operating Activities -$13.31M -$13.27M -$11.68M
YoY Change 30.75% 13.57% -34.23%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K $1.000K $10.00K
YoY Change 100.0% -90.0% -97.5%
Acquisitions
YoY Change
Other Investing Activities $8.360M $17.96M $8.700M
YoY Change -40.24% 106.44% -40.7%
Cash From Investing Activities $8.340M $17.96M $8.690M
YoY Change -40.39% 106.65% -39.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -20.00K 261.0K -730.0K
YoY Change -97.18% -135.75% 10.61%
NET CHANGE
Cash From Operating Activities -13.31M -13.27M -11.68M
Cash From Investing Activities 8.340M 17.96M 8.690M
Cash From Financing Activities -20.00K 261.0K -730.0K
Net Change In Cash -4.990M 4.954M -3.720M
YoY Change -260.97% -233.17% -10.36%
FREE CASH FLOW
Cash From Operating Activities -$13.31M -$13.27M -$11.68M
Capital Expenditures -$20.00K $1.000K $10.00K
Free Cash Flow -$13.29M -$13.27M -$11.69M
YoY Change 30.68% 13.48% -35.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27563346 shares
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28632000
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3661000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27558883 shares
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
28000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
91422000
CY2018Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
78937000
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
564000
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
370551000
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3796000
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-49000
CY2018Q1 us-gaap Assets
Assets
92614000
CY2018Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2018Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2018Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
43386000
CY2018Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
43339000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45731000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27558883 shares
CY2018Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
35598000
CY2018Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
89100000
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
836000
CY2018Q1 us-gaap Liabilities
Liabilities
27617000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92614000
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7457000
CY2018Q1 us-gaap Long Term Debt
LongTermDebt
20000000
CY2018Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
7273000
CY2018Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7273000
CY2018Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5454000
CY2018Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2018Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
20160000
CY2018Q1 us-gaap Notes Payable
NotesPayable
20200000
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
186000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
226000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1050000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
464000
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
132000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
360000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1420000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
479000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-305533000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
64997000
CY2018Q1 zfgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2075000
CY2018Q1 zfgn Line Of Credit Facility Debt Default Minimum Amount
LineOfCreditFacilityDebtDefaultMinimumAmount
300000
CY2018Q1 zfgn Tax Incentive Receivable Noncurrent
TaxIncentiveReceivableNoncurrent
581000
CY2018Q1 zfgn Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
932000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32352000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4273000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
104925000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
78624000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
292000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
367825000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3020000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-58000
CY2017Q4 us-gaap Assets
Assets
105510000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
58000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
61333000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
61275000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40777000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27489457 shares
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
17349000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27489457 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2229000
CY2017Q4 us-gaap Liabilities
Liabilities
27293000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105510000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7293000
CY2017Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
20000000
CY2017Q4 us-gaap Notes Payable
NotesPayable
20000000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
105000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
57000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1927000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
528000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-289577000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
78217000
CY2017Q4 zfgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1647000
CY2017Q4 zfgn Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
946000
CY2017Q4 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
20000000
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03 pure
zfgn Net Proceeds From Sale Of Securities
NetProceedsFromSaleOfSecurities
333300000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2001000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4064974 shares
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3720000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12994000
CY2017Q1 us-gaap Depreciation
Depreciation
41000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
100000
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
21000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3588000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
132000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-662000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20000
CY2017Q1 us-gaap Interest Expense
InterestExpense
73000
CY2017Q1 us-gaap Investment Income Net
InvestmentIncomeNet
227000
CY2017Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-64000
CY2017Q1 us-gaap Interest Paid
InterestPaid
59000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
8691000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11679000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
13265000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-732000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-13011000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13265000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
254000
CY2017Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
17000
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
17000
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2017Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
7000
CY2017Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
32792000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
CY2017Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
40000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
41493000
CY2017Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
772000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9677000
CY2017Q1 us-gaap Revenues
Revenues
0
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2001000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27350673 shares
CY2017Q1 zfgn Premium On Marketable Securities
PremiumOnMarketableSecurities
210000
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2466000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5852654 shares
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4954000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15947000
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 us-gaap Depreciation
Depreciation
50000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
Zafgen, Inc.
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001374690
CY2018Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-22
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-63000
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-14000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3269000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-527000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
776000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-507000
CY2018Q1 us-gaap Interest Expense
InterestExpense
458000
CY2018Q1 us-gaap Investment Income Net
InvestmentIncomeNet
267000
CY2018Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
11000
CY2018Q1 us-gaap Interest Paid
InterestPaid
198000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
17958000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13265000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
15702000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
261000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-15956000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15702000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-254000
CY2018Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
9000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9000
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2018Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
12880000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
CY2018Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
261000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
30839000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12433000
CY2018Q1 us-gaap Revenues
Revenues
0
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2466000
CY2018Q1 dei Trading Symbol
TradingSymbol
ZFGN
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27541594 shares
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#x2019;s estimates.</p> </div>
CY2018Q1 zfgn Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
581000
CY2018Q1 zfgn Premium On Marketable Securities
PremiumOnMarketableSecurities
3000

Files In Submission

Name View Source Status
0001193125-18-159281-index-headers.html Edgar Link pending
0001193125-18-159281-index.html Edgar Link pending
0001193125-18-159281.txt Edgar Link pending
0001193125-18-159281-xbrl.zip Edgar Link pending
d361020d10q.htm Edgar Link pending
d361020dex311.htm Edgar Link pending
d361020dex312.htm Edgar Link pending
d361020dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zfgn-20180331.xml Edgar Link completed
zfgn-20180331.xsd Edgar Link pending
zfgn-20180331_cal.xml Edgar Link unprocessable
zfgn-20180331_def.xml Edgar Link unprocessable
zfgn-20180331_lab.xml Edgar Link unprocessable
zfgn-20180331_pre.xml Edgar Link unprocessable